CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients

Bruno Cassinat; Emmanuelle Verger; Nabih Maslah; Nicolas Gauthier; William Vainchenker; Stéphane Giraudier; Jean-Jacques Kiladjian

doi:10.3324/haematol.2020.252643

CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients

Haematologica. 2021 Mar 1;106(3):863-864. doi: 10.3324/haematol.2020.252643.

Authors

Bruno Cassinat^{1

2

3}, Emmanuelle Verger^{1

2}, Nabih Maslah^{1

2}, Nicolas Gauthier⁴, William Vainchenker^{3

5}, Stéphane Giraudier^{1

2

3}, Jean-Jacques Kiladjian^{2

3

4}

Affiliations

¹ AP-HP, Laboratoire de Biologie Cellulaire, Hôpital Saint-Louis, Paris
² Université de Paris, U1131 INSERM, Paris
³ Laboratoire d’Excellence GR-Ex, Université de Paris, Paris
⁴ Centre d’Investigations Cliniques, Hôpital Saint-Louis, Paris
⁵ Université de Paris-Saclay, INSERM UMR1287, Institut Gustave Roussy, Villejuif, France

No abstract available

Publication types

Letter

MeSH terms

Bone Marrow Neoplasms*
Cyclin D2
Drug Resistance, Neoplasm
Fusion Proteins, bcr-abl / genetics
Humans
Mutation
Myeloproliferative Disorders* / genetics

Substances

CCND2 protein, human
Cyclin D2
Fusion Proteins, bcr-abl